These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23658481)

  • 1. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.
    Panos RJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():221-30. PubMed ID: 23658481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
    Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
    J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
    Kässner F; Hodder R; Bateman ED
    Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease.
    Gordon J; Panos RJ
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):381-92. PubMed ID: 20163324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.
    Ferguson GT; Ghafouri M; Dai L; Dunn LJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():139-50. PubMed ID: 23658479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.
    Kesten S; Israel E; Li G; Mitchell J; Wise R; Stern T
    Pulm Pharmacol Ther; 2018 Dec; 53():27-32. PubMed ID: 30201410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
    Hodder R; Price D
    Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
    Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies.
    Koehler D; Pavia D; Dewberry H; Hodder R
    Respiration; 2004; 71(5):469-76. PubMed ID: 15467324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Environmental Impact of the Reusable Respimat
    Hänsel M; Bambach T; Wachtel H
    Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
    Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
    Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
    Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
    Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
    von Berg A; Jeena PM; Soemantri PA; Vertruyen A; Schmidt P; Gerken F; Razzouk H
    Pediatr Pulmonol; 2004 Mar; 37(3):264-72. PubMed ID: 14966821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.
    Ferguson GT; Dalby RN
    Postgrad Med; 2018 Aug; 130(6):515-522. PubMed ID: 29972656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Respimat Soft Mist inhaler in COPD patients.
    Anderson P
    Int J Chron Obstruct Pulmon Dis; 2006; 1(3):251-9. PubMed ID: 18046862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
    Schürmann W; Schmidtmann S; Moroni P; Massey D; Qidan M
    Treat Respir Med; 2005; 4(1):53-61. PubMed ID: 15725050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.